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Background. Proteinuria is a marker of cardiovascular and
renal disease in patients with chronic kidney disease (CKD),
and reduction in proteinuria has been associated with improved
cardiovascular and renal outcomes. While active vitamin D and
its analogs have been shown to have renal protective effects in
animals, these hormones have not been shown to reduce pro-
teinuria in CKD patients.
Methods. In three double-blind, randomized, placebo-
controlled studies to evaluate the safety and efficacy of oral
paricalcitol, 220 CKD stage 3 and 4 patients with secondary
hyperparathyroidism (SHPT) were randomized to oral parical-
citol (N = 107, mean dose 9.5 lg/week) or placebo (N = 113)
and followed for up to 24 weeks. In conjunction with other safety
measures, proteinuria was measured by dipstick and read by an
automated reader at the beginning and end of trial. We sub-
sequently analyzed the dipstick data to evaluate the effect of
paricalcitol on proteinuria.
Results. At baseline, proteinuria was present in 57 patients
randomized to oral paricalcitol and 61patients randomized to
placebo (NS). At the final visit, 29/57 (51%) of the paricalcitol
patients compared to 15/61 (25%) placebo patients had reduc-
tion in proteinuria, P = 0.004 (odds for reduction in proteinuria
3.2 times greater for paricalcitol patients, 95% CI 1.5–6.9). For
the patients who had both proteinuria at baseline and parathy-
roid hormone (PTH) suppression (end point defined as 2 con-
secutive ≥30% decreases in iPTH from baseline), 27/51 (53%)
patients had a reduction in the proteinuria in the paricalcitol
group and 0/7 (0%) had a reduction in proteinuria in the placebo
group. Reduction of proteinuria favored patients on paricalci-
tol, regardless of age, sex, race, diabetes mellitus, hypertension,
or use of therapies to block the renin-angiotensin-aldosterone
system (RAAS).
Conclusion. Our results demonstrate that the reduction in
proteinuria was associated with paricalcitol treatment, and the
reduction in proteinuria was independent of concomitant use of
agents that block the RAAS. Paricalcitol as a potential pharma-
Key words: paricalcitol, chronic kidney disease, proteinuria, vitamin D.
Received for publication May 18, 2005
and in revised form June 13, 2005
Accepted for publication July 8, 2005
C© 2005 by the International Society of Nephrology
cologic means of reducing proteinuria in CKD patients warrants
further investigation.
Proteinuria is not only a capital sign of kidney dis-
ease, but also a marker of chronic kidney disease (CKD)
progression, and a marker of cardiovascular disease and
death [1]. Moreover, reduction in proteinuria has been
linked to improvement in both cardiovascular and renal
outcomes [2] and, therefore, strategies that reduce pro-
teinuria are considered beneficial.
Blood pressure reduction using inhibitors of the
renin-angiotensin-aldosterone system (RAAS), namely
angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin II receptor blockers (ARBs) is currently the
standard of care for reducing proteinuria and improving
cardiovascular and renal outcomes [3]. However, active
vitamin D and its analogs also have unique effects on the
kidney that involve the renin-angiotensin-aldosterone
system [4], and these agents have demonstrated renal pro-
tective effects in animal studies [5]. Additionally, studies
in CKD patients suggest a role of active vitamin D in
abrogating renal disease [6] and providing cardiovascu-
lar protection [7, 8]. Despite the use of agents that in-
hibit RAAS, renal and cardiac disease tend to progress
in CKD patients and this progression seems to correlate
with residual proteinuria [2, 9, 10]. If, in fact, active vi-
tamin D affects proteinuria reduction, this finding would
warrant further investigation as a potential novel ther-
apy, along with preexisting therapies that could provide
additional cardiovascular and renal protective benefits in
CKD patients. In this report, we evaluated the effect of
paricalcitol compared to placebo on proteinuria (origi-
nally examined as a safety measure) in predialysis CKD
patients with secondary hyperparathyroidism (SHPT).
METHODS
Patients and study design
Results from three double-blind, randomized, placebo-
controlled trials comparing paricalcitol capsule and
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placebo for the suppression of parathyroid hormone
(PTH) in 220 patients who were enrolled at 46 sites in
the United States and Poland between April 3, 2002 and
March 3, 2004, were examined. Across these trials, 107
patients were randomly assigned to the paricalcitol cap-
sule group and 113 were randomly assigned to placebo
group.
The inclusion/exclusion criteria were identical for all
three trials. Eligible patients were men and women
≥18 years of age who had been in the care of a physi-
cian ≥2 months for CKD prior to entry into the study,
and had not been on active vitamin D therapy for at least
4 weeks prior to the screening visit. Patients were re-
quired to have an average of 2 consecutive iPTH values of
≥150 pg/mL, 2 consecutive serum calcium levels between
8.0 to 10.0 mg/dL, 2 consecutive serum phosphorus lev-
els of ≤5.2 mg/dL within 4 weeks prior to treatment, and
patients who had an estimated glomerular filtration rate
(eGFR) of 15 to 60 mL/min and who were not expected
to begin dialysis for at least 6 months.
Because the study was designed to evaluate the ef-
ficacy of oral paricalcitol on PTH control, proteinuria
was not considered to be an inclusion or exclusion cri-
teria. Patients were randomized to either oral paricalci-
tol or placebo, and were followed for up to 24 weeks.
In two trials a three-times-weekly (TIW) dosing regimen
was used, and the initial dose was 2 or 4 lg depending
on baseline iPTH levels (2 lg if iPTH was ≤500 pg/mL
and 4 lg if iPTH was >500 pg/mL). In the third trial a
once-daily (QD) dosing regimen was used, and the ini-
tial dose was 1 lg if iPTH was ≤500 pg/mL and 2 lg if
iPTH was >500 pg/mL. Doses thereafter were titrated in
2 lg (TIW regimen) or 1 lg (QD regimen) increments
based on PTH, calcium, and phosphorus values. Princi-
pal investigators made every attempt to maintain a stable
dose of all concurrent medications, including ACEi and
ARB use, during the treatment phase. All patients signed
informed consent prior to enrollment, and the study was
approved by the local Institutional Review Board of each
participating center.
All blood and urine tests were performed in a central
laboratory (Covance, Indianapolis, IN, USA). For each
patient, GFR was estimated using the modified MDRD
study formula [GFR = 170 × (Scr)−0·999 × (Age)−0·167 ×
(0.762 if patient is female) × (1.180 if patient is black) ×
(BUN)−0·170 × (Alb)+0·318 [11]. As part of the urinaly-
sis, semiquantitative dipstick proteinuria was measured
using IRIStripsTM (Roche Diagnostics Corporation,
Indianapolis, IN, USA) at baseline (prior to study drug
administration) and at the end of the study (final visit).
Urine dipstick results were analyzed using an automated
reader (IRIS CHEMSTRIP reader Model 500, Interna-
tional Remote Imaging Systems, Inc., Chatsworth CA)
and were reported as negative, trace, 1+, 2+ and 3+. Re-
duction of proteinuria was not a pre-specified end-point,
therefore urine protein/creatinine ratios were not mea-
sured, nor urine specimens archived for future measure-
ments.
Statistical analyses
The primary analysis consisted of a comparison of the
proportion of paricalcitol and placebo patients who had
dipstick proteinuria at baseline that subsequently experi-
enced a decrease from baseline using Fisher’s exact test.
The proportion of paricalcitol and placebo patients that
experienced a decrease from baseline in proteinuria were
compared using Fisher’s exact test within subpopulations
of age, race, sex, baseline diabetes mellitus status, baseline
hypertension status, and use of ACEi/ARB. The Breslow-
Day test was performed to compare the odds ratio (for
paricalcitol patients to placebo patients) of a decrease in
proteinuria across subpopulations of age, race, sex, base-
line diabetes mellitus status, baseline hypertension status,
and use of ACEi/ARB.
Response to PTH suppression was defined a priori as
two consecutive reductions in iPTH of at least 30% from
baseline. The proportion of paricalcitol and placebo pa-
tients that experienced a decrease from baseline in pro-
teinuria were compared within the set of patients with
PTH response and the set of patients without PTH re-
sponse using Fisher exact test. A comparison of the odds
ratio (for paricalcitol patients to placebo patients) for a
decrease in proteinuria between the two sets of patients
was performed with a Breslow-Day test.
For patients who had dipstick proteinuria at base-
line, mean change from baseline to final visit in eGFR,
mean change from baseline to weeks 7, 15, and final visit
in systolic and diastolic blood pressure were compared
between the paricalcitol and placebo treatment groups
using a one-way analysis of variance (ANOVA) with
treatment group as the factor.
A test for an association between baseline iPTH and
baseline proteinuria was performed using a linear model
with baseline iPTH as a continuous response variable and
baseline proteinuria as a discrete factor.
RESULTS
Of the 220 subjects enrolled in three studies, 195 sub-
jects had tests for dipstick urinalysis at the beginning and
the end of study. Baseline and demographic characteris-
tics of these 195 patients who received oral paricalcitol or
placebo are shown in Table 1 and reveal no major differ-
ences between groups. The mean dose of oral paricalcitol
was 9.5 lg/week.
Effect of oral paricalcitol on dipstick proteinuria
Shifts in urine protein from baseline to final visit are
shown in Figure 1. The percent of patients who experience
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Table 1. Demographic and baseline characteristics
Paricalcitol
capsule Placebo
(N = 94) (N = 101) P valuea
Sex
Female 31 (33%) 33 (33%) >0.999
Male 63 (67%) 68 (67%) 0.256
Race
White 66 (70%) 74 (73%)
Black 23 (24%) 26 (26%)
Other 5 (5%) 1 (1%)
Age years 0.571
Mean (SD) 62.8 (13.1) 61.7 (12.3)
Time since CKD 0.065
diagnosis years
Mean (SD) 4.7 (4.5) 6.4 (7.7)
Smoking status 0.564
Yes 57 (61%) 57 (56%)
No 37 (39%) 42 (42%)
Diabetic status >0.999
Yes 55 (59%) 59 (58%)
No 39 (41%) 42 (42%)
ACEi/ARB use 0.758
Yes 64 (68%) 71 (70%)
No 30 (32%) 30 (30%)
Body weight kg 0.435
Mean (SD) 94.0 (22.0) 91.3 (25.6)
SBP mm Hg 0.859
Mean (SD) 136.5 (21.1) 135.9 (20.1)
DBP mm Hg 0.712
Mean (SD) 72.4 (12.6) 73.5 (12.2)
eGFR mL/min/1.73m2 0.615
Mean (SD) [Range] 23.5 (8.3) [10-46] 22.9 (7.4) [13-47.1]
iPTH pg/mL 0.253
Mean (SD) 262.6 (112.8) 282.4 (126.4)
Calcium mg/mL 0.149
Mean (SD) 9.3 (0.4) 9.4 (0.4)
Phosphorus mg/mL 0.808
Mean (SD) 4.0 (0.5) 4.0 (0.6)
Albumin mg/mL 0.228
Mean (SD) 3.9 (0.5) 3.9 (0.4)
Cholesterol mg/mL 0.787
Mean (SD) 180.3 (42.8) 178.6 (44.7)
Hemoglobin mg/dL 0.713
Mean (SD) 12.0 (1.5) 12.0 (1.6)
aP values for comparisons of categorical data are from Fisher exact test.
P values for comparisons of means are from a one-way analysis of variance
(ANOVA), with treatment group as the factor.
a shift is plotted against the baseline level of urine protein
dipstick in the placebo and paricalcitol groups. The num-
bers below the figure show the actual number of patients
who had shifts in urine protein dipstick results. Ninety-
four oral paricalcitol patients and 101 placebo patients
had baseline and final visit proteinuria measurements. Of
the 94 patients who received oral paricalcitol, 29 (31%)
had a reduction in proteinuria, 47 (50%) had no change
in proteinuria, and 18 (19%) had an increase in protein-
uria. In contrast, of the 101 placebo patients, 15 (15%)
had reduction in proteinuria, 63 (62%) had no change in
proteinuria, and 23 (23%) had an increase in proteinuria.
The effect of oral paricalcitol on the reduction of pro-
teinuria was further examined in the set of patients in
whom a decrease in proteinuria could be detected by the
dipstick approach (i.e., those patients who had protein-
uria at baseline). In other words, this group of 118 patients
who had baseline proteinuria is the subset of 195 patients
who had dipstick urinalysis at baseline. There were 57 and
61 such patients in the paricalcitol and placebo groups, re-
spectively. Of the 57 paricalcitol patients, 29 (51%) had
reduction in proteinuria compared to 15 of the 61 (25%)
placebo patients (P = 0.004) (Fig. 2). The odds of reduc-
tion in proteinuria was 3.2 times greater (95% CI 1.5–
6.9) for oral paricalcitol–treated patients than placebo
patients.
Urine dipstick proteinuria can be influenced by urine
specific gravity [12, 13]. The urine specific gravity was
1.014 at baseline and 1.013 at final visit in the placebo
group, a change of −0.001 ± 0.006, which was not signif-
icant. The urine-specific gravity in the paricalcitol group
was 1.013 at baseline and final visit. The mean difference
between the groups of 0.001 ± 0.001 (P = 0.111) showed
that there was no difference in urine-specific gravity be-
tween groups. After adjusting for baseline urine-specific
gravity for 118 patients who had proteinuria at baseline,
there was a difference between paricalcitol and placebo
in decrease in proteinuria (P = 0.001), with the odds of
a reduction 4 times higher for paricalcitol compared to
placebo. The unadjusted reduction was only 3.2 times.
Accordingly, the improvement in proteinuria in the par-
icalcitol group cannot be ascribed to changes in specific
gravity.
Further analysis revealed that of patients who were
on ACEi/ARB therapy and had proteinuria at baseline,
52% (22/42) of paricalcitol patients versus 27% (11/41)
of placebo patients had a decrease in proteinuria (P =
0.025) (Fig. 2). There was no statistically significant dif-
ference between paricalcitol and placebo groups in mean
eGFR change from baseline to the final visit (−2.50 ± 0.54
vs. −3.0 ± 0.53 mL/min/1.73m2, respectively, P = 0.51).
We also measured blood pressure at baseline, week 7,
week 15, and the final visit, with no statistically signif-
icant difference between the two groups for the mean
change of systolic blood pressure/diastolic blood pres-
sure (SBP/DBP) at each visit and from baseline to the
final visit (data not shown).
Effect of PTH reduction, concomitant therapy, and
baseline characteristics on reduction in proteinuria
A significant association between baseline iPTH lev-
els and levels of baseline proteinuria was not found (P =
0.20). In addition, iPTH reduction alone may not reduce
urinary protein. Response in iPTH was defined a priori
as two consecutive ≥30% reductions in iPTH from base-
line. Fifty-four oral paricalcitol patients and 59 placebo
patients had both proteinuria at baseline and iPTH data
and were included in the analysis. In the oral paricalcitol
group, 27 of 51 (53%) iPTH responders and 1 of 3 (33%)
nonresponders had reduction in protein. In the placebo
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Fig. 1. The percent of patients who experience improvement and worsening of proteinuria. The x-axis represents the baseline level of proteinuria
and the y-axis the end of study proteinuria expressed as a percent. Increasing intensity of gray represents increasing severity of proteinuria. The
actual numbers of patients who experienced regression and progression of proteinuria are denoted in the table that appears below the figure.
The shaded diagonal in the table represents those patients who had no change in proteinuria category. The overall intensity of color is higher in the
placebo group compared to paricalcitol group, which represents overall improvement in dipstick proteinuria with paricalcitol.
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Overall group ACEi/ARB users
29/57 (51%) 15/61 (25%) 22/42 (52%) 11/41 (27%)
P = 0.025P = 0.004
Paricalcitol
Placebo
Fig. 2. Of the 195 patients who had evaluation of proteinuria at baseline and end of study, 118 had dipstick proteinuria at baseline. Of these,
57 patients were in the paricalcitol group and 61 in the placebo group. Figure shows that the odds of reduction of proteinuria were 3.2 times
higher in the paricalcitol compared to placebo group. In the subgroup of 83 patients who had dipstick proteinuria at baseline and also who used
angiotensin-converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB), paricalcitol use was associated with greater reduction
in dipstick proteinuria.
group, none of 7 responders (0%) and 14 of 52 nonre-
sponders (27%) had reduction in proteinuria. Whereas
reduction in urinary protein in the nonresponders was
similar between the oral paricalcitol and placebo groups
(33% and 27%, respectively, P > 0.999), more than half
the responders (53%) in the oral paricalcitol compared
to none in the placebo group had reduction in protein-
uria (P = 0.012). A comparison between the two set of
patients in the odds of reduction in proteinuria resulted
in a P value of 0.068.
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Table 2. Effect of clinical characteristics of reduction of dipstick
Paricalcitol (N = 57) Placebo (N = 61) Odds ratio (95% CI)
Fisher exact test, and Breslow-Day test for
Characteristic Decreased Proteinuria Decreased Proteinuria P value homogeneity of odds ratios
Total Yes No Yes No 0.004 3.2 (1.5, 6.9)
29 (51%) 28 (49%) 15 (25%) 46 (75%)
Gender
Male 18 (49%) 19 (51%) 13 (32%) 28 (68%) 0.166 2.0 (0.8, 5.1) 0.080
Female 11 (55%) 9 (45%) 2 (10%) 18 (90%) 0.006 11.0 (2.3, 52.7)
Age
≥65 15 (65%) 8 (35%) 6 (27%) 16 (73%) 0.017 5.0 (1.4, 17.5) 0.357
<65 14 (41%) 20 (59%) 9 (23%) 30 (77%) 0.131 2.3 (0.9, 6.4)
Race
Black 11 (65%) 11 (65%) 6 (33%) 12 (67%) 0.094 3.7 (0.9, 14.8) 0.844
Other 18 (45%) 22 (55%) 9 (21%) 34 (79%) 0.034 3.1 (1.2, 8.0)
Diabetes mellitus
Yes 18 (49%) 19 (51%) 11 (28%) 28 (72%) 0.098 2.4 (0.9, 6.2) 0.550
No 1 (50%) 1 (50%) 1 (50%) 1 (50%) 1.000 1.0 (not defined)
ACEi/ARB
Yes 22 (52%) 20 (48%) 11 (27%) 30 (73%) 0.025 3.0 (1.2, 7.5) 0.863
No 7 (47%) 8 (53%) 4 (20%) 16 (80%) 0.144 3.5 (0.8, 15.4)
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
The odds of a reduction in proteinuria for paricalcitol
patients were consistently greater compared to placebo
patients for subpopulations of age, race, sex, diabetes
mellitus, presence or absence of hypertension, and use
of agents to block the renin-angiotensin-aldosterone sys-
tem (Table 2). Additionally, none of these factors were
found to be predictive of reduction in proteinuria.
DISCUSSION
The pooled results from three randomized, double-
blind, placebo-controlled studies, which evaluated the
safety and efficacy of oral paricalcitol in stage 3 and 4
CKD patients with SHPT, showed that more paricalcitol
treated patients had a reduction in dipstick proteinuria
compared to placebo. These findings were independent
of RAAS blockade by ACEi/ARBs. The odds of reduc-
tion in proteinuria were 3.2-fold higher in the paricalcitol
group compared to placebo. The reduction in proteinuria
was not due to a reduction in urine specific gravity in the
paricalcitol group. In fact, adjustment for urine specific
gravity increased the adjusted odds of reduction of dip-
stick protein from 3.2 to 4.0. It is hard to separate the
effect of vitamin D on PTH reduction and proteinuria
reduction in our clinical study. However, the reduction of
proteinuria by paricalcitol may not be only dependent on
PTH reduction since the data showed that iPTH reduc-
tion alone (by placebo) did not reduce urinary protein.
Whether paricalcitol reduces proteinuria via reduction of
PTH or not, it would offer additional information on the
mechanism of protection but would not alter the overall
result of the study.
The reduction in proteinuria seen in this study is bio-
logically plausible and several mechanisms can be pos-
tulated for reduction in proteinuria. In patients with
kidney transplants, cohort studies have reported a better
graft survival and reduced rate of loss of graft function
in calcitriol-treated patients [6]. Various animal mod-
els of renal disease have demonstrated attenuation of
glomerular [5, 14–17] and tubulointerstitial injury [16].
For example, Schwarz et al administered calcitriol to
5/6 nephrectomized rats and found that there was reduc-
tion in albuminuria, improvement in glomerulosclerosis,
and improvement in tubular function [5].
Proximal tubules are the site of calcitriol synthesis. A
stable concentration of the endogenous active form of
vitamin D or vitamin D receptor activator (VDRA) in
the kidney may be required to maintain the structural
integrity of the kidney. The direct effects of vitamin D
on inflammation [18, 19], proliferation of mesangial cells
[20], and proximal tubular cells [21] may account for
these salutary effects. Finally, these effects on renal pro-
tection appear to be independent of PTH. In subtotally
nephrectomized parathyroidectomized animals, prolifer-
ative PCNA-positive cells were attenuated with vitamin
D treatment [16].
Vitamin D has an important regulatory effect on the
renin-angiotensin-aldosterone system [4]. Li et al have
shown through a series of elegant experiments that in
vitamin D receptor mutant mice, renin production is in-
creased [4]. Induction of vitamin D deficiency in wild-type
mice also results in enhanced renin production. However,
the regulation of renin via dietary sodium intake is main-
tained in these animals. Li et al also demonstrated that
the enhanced renin production is independent of ionized
calcium or PTH levels and the renin mRNA expression
could be reduced by the use of activated vitamin D [4].
Vitamin D also appears to regulate systemic arterial
pressure via its non-PTH actions. In both hypertensive
and normotensive humans, blood pressure was shown
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to be inversely related to vitamin D levels [22]. In ad-
dition, in cell culture models [23] and in patients with
CKD [7], calcitriol was associated with regression of
myocyte hypertrophy. The use of active vitamin D has
been associated with improved all-cause and cardiovas-
cular mortality [8], and paricalcitol use was associated
with a greater survival benefit compared to calcitriol in
hemodialysis patients [24]. Given the totality of current
data (prospective and retrospective), which suggests a
potential role of paricalcitol on cardiovascular and renal
protection, further investigations are clearly warranted.
Limitations of the current study include the method
of detection of proteinuria (automated dipstick vs. spot
urinary protein/creatinine or albumin/creatinine ratio).
Interestingly enough, the degree of association between
active vitamin D use and reduction in proteinuria may
have been even stronger with the more precise spot uri-
nary tests of proteinuria. In previous studies, dipstick pro-
teinuria has been found to be a good predictor of spot
urine protein/creatinine ratios [12, 13].
CONCLUSION
Our study noted a reduction in proteinuria detected
semiquantitatively by dipstick using an automated anal-
ysis in stage 3 and 4 CKD patients with SHPT treated
with oral paricalcitol. This reduction in proteinuria oc-
curred in the face of the frequent use of agents that block
the RAAS. Given the association between reduction in
proteinuria and renal and cardiovascular protection, the
role of paricalcitol on these disease states warrants fur-
ther investigation in randomized, controlled trials using
quantitative assays for albumin excretion.
Reprint requests to Rajiv Agarwal, M.D., VAMC, 111N 1481 West
10th Street, Indianapolis, IN 46202.
E-mail: ragarwal@iupui.edu
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